Viewing Study NCT02500290



Ignite Creation Date: 2024-05-06 @ 7:16 AM
Last Modification Date: 2024-10-26 @ 11:46 AM
Study NCT ID: NCT02500290
Status: UNKNOWN
Last Update Posted: 2019-06-19
First Post: 2015-07-07

Brief Title: Antiplatelet Therapy in Acute Coronary SyndromeACS Safety and Efficacy of Switching Antiplatelet
Sponsor: Fundación Pública Andaluza Progreso y Salud
Organization: Andalusian Network for Design and Translation of Advanced Therapies

Study Overview

Official Title: Antiplatelet Therapy in Acute Coronary Syndrome ACS Safety and Efficacy of Switching Antiplatelet
Status: UNKNOWN
Status Verified Date: 2019-02
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study aims to describe antiplatelet therapy in ACS in Andalusia and make an assessment of efficacy and safety of hospital use Prasugrel ticagrelor vs Clopidogrel and Prasugrel switching to ticagrelor patients pretreated with clopidogrel
Detailed Description: The management of acute coronary syndrome has changed in recent years as reflected in the new Clinical Practice Guidelines of the European Society of Cardiology for the management of ACS with or without ST segment elevation with the development and increased accessibility of the angiography and percutaneous coronary intervention and the arrival of the new antiplatelet Prasugrel and Ticagrelor

The ACS encompasses several clinical entities where dual antiplatelet therapy remains the basis of antiplatelet therapy and one of the mainstays of treatment But the emergence of Prasugrel and Ticagrelor have changed the classical management with aspirin plus clopidogre

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None